Enterobacteriaceae Infections Clinical Trial
Multidrug-resistant Enterobacteriaceae producing extended-spectrum β-lactamases (hereafter
called ESBLs) have emerged as an important cause of bloodstream infection in hospitalized
patients and urinary tract infections in the community. As is the case with other
multidrug-resistant organisms chronic colonization is frequent, in the case of ESBLs mostly
intestinal and urinary carriage.
To the investigators knowledge no randomized, placebo-controlled clinical trial has been
performed to study the efficacy of a systematic ESBL eradication strategy. Eradication of
ESBL carriage would cause benefits for the individual patient - by reducing the risk of
infection - and for the community - by reducing transmission. Even if eradication turns out
to be impossible, transient suppression of ESBL might reduce the likelihood of transmission
and thus still be beneficial from an ecologic perspective.
The purpose of the proposed study is to test the hypothesis that the administration of a 10
day course of oral antibiotics active against ESBLs can lead to decolonization of ESBL
carriage in hospitalized patients.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02400268 -
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
|
Phase 3 | |
Completed |
NCT03401242 -
Prevalence of ESBL and CPE in French Nursing Homes
|
||
Not yet recruiting |
NCT03967301 -
Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics
|
N/A | |
Completed |
NCT02795949 -
Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae
|
Phase 3 | |
Completed |
NCT00573235 -
Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli
|
||
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00573521 -
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
|
||
Recruiting |
NCT03671967 -
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
|
Phase 4 | |
Enrolling by invitation |
NCT03924934 -
Community-associated Highly-Resistant Enterobacterales
|
||
Completed |
NCT03477084 -
Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities
|
||
Not yet recruiting |
NCT05632315 -
PMT for MDRO Decolonization
|
Phase 2 | |
Withdrawn |
NCT03527056 -
Pilot Study Using Oral Capsule FMT to Decolonize GI CRE
|
Early Phase 1 | |
Not yet recruiting |
NCT04903886 -
Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae
|
||
Completed |
NCT02482051 -
Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood
|
||
Recruiting |
NCT00894036 -
The Burden and Genetic Variability of Extended-Spectrum ß-Lactamase (ESBL) - Producing Pathogens in Swiss Children
|
N/A | |
Suspended |
NCT05355350 -
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
|
Phase 4 | |
Recruiting |
NCT05516433 -
Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria
|
||
Recruiting |
NCT02450942 -
18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection
|
Early Phase 1 | |
Recruiting |
NCT05035342 -
Fecal Transplantation to Eradicate Colonizing Emergent Superbugs
|
Phase 3 | |
Not yet recruiting |
NCT03411590 -
The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers
|
N/A |